28.09.2023 - TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the .
28.08.2023 - Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment demonstrates Medicenna’s continuing commitment to . Seite 1